Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Lebwohl

Showing results (11-20 of 209) with videos related to

Pageof 21
Sort By:
Journal of the American Academy of Dermatology|April 26, 2006
Hat-wearing patterns in persons attending baseball gamesAshlee S Rigel, Mark G Lebwohl
Expert Opinion on Biological Therapy|November 1, 2005
Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonistVicky Kwan Wong, Mark G Lebwohl
International Journal of Dermatology|September 25, 2018
Review of safety and efficacy of approved systemic psoriasis therapiesShivani B Kaushik, Mark G Lebwohl
Journal of the American Academy of Dermatology|July 19, 2018
Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agentsShivani B Kaushik, Mark G Lebwohl
Journal of Drugs in Dermatology : JDD|March 15, 2018
Onset of Action of Biologics in Patients With Moderate-to-Severe PsoriasisKim A Papp, Mark G Lebwohl
JAMA Dermatology|November 29, 2013
Biopsy techniques: shave, punch, or excision?Robert G Phelps, Mark G Lebwohl
Dermatologic Clinics|November 24, 2018
Biologics and Psoriasis: The Beat Goes OnHee J Kim, Mark G Lebwohl
Journal of Drugs in Dermatology : JDD|March 26, 2019
Onset of Action of Antipsoriatic Drugs for Moderate-to-Severe Plaque Psoriasis: An UpdateChristopher J. Yao, Mark G. Lebwohl
Journal of the American Academy of Dermatology|June 18, 2026
RE: Comment on ''The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial''Matthew S Goldberg, Mark G Lebwohl
Journal of the American Academy of Dermatology|July 19, 2018
Psoriasis: Which therapy for which patient: Focus on special populations and chronic infectionsShivani B Kaushik, Mark G Lebwohl
Pageof 21

Showing results (11-20 of 209) with videos related to

Sort By:
Pageof 21
Journal of the American Academy of Dermatology|April 26, 2006
Hat-wearing patterns in persons attending baseball gamesAshlee S Rigel, Mark G Lebwohl
Expert Opinion on Biological Therapy|November 1, 2005
Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonistVicky Kwan Wong, Mark G Lebwohl
International Journal of Dermatology|September 25, 2018
Review of safety and efficacy of approved systemic psoriasis therapiesShivani B Kaushik, Mark G Lebwohl
Journal of the American Academy of Dermatology|July 19, 2018
Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agentsShivani B Kaushik, Mark G Lebwohl
Journal of Drugs in Dermatology : JDD|March 15, 2018
Onset of Action of Biologics in Patients With Moderate-to-Severe PsoriasisKim A Papp, Mark G Lebwohl
JAMA Dermatology|November 29, 2013
Biopsy techniques: shave, punch, or excision?Robert G Phelps, Mark G Lebwohl
Dermatologic Clinics|November 24, 2018
Biologics and Psoriasis: The Beat Goes OnHee J Kim, Mark G Lebwohl
Journal of Drugs in Dermatology : JDD|March 26, 2019
Onset of Action of Antipsoriatic Drugs for Moderate-to-Severe Plaque Psoriasis: An UpdateChristopher J. Yao, Mark G. Lebwohl
Journal of the American Academy of Dermatology|June 18, 2026
RE: Comment on ''The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial''Matthew S Goldberg, Mark G Lebwohl
Journal of the American Academy of Dermatology|July 19, 2018
Psoriasis: Which therapy for which patient: Focus on special populations and chronic infectionsShivani B Kaushik, Mark G Lebwohl
Pageof 21